Summary of ADC Therapeutics SA Lotus 7 Update Conference Call Company and Industry Overview - **Company**: ADC Therapeutics SA - **Industry**: Oncology, specifically focusing on therapies for Diffuse Large B-Cell Lymphoma (DLBCL) Key Points and Arguments 1. **Clinical Trial Update**: ADC Therapeutics announced updated results from the LOTIS-7 clinical trial, focusing on the combination of Zynlonta and glofitamab for treating DLBCL [2][10] 2. **Zynlonta's Profile**: Zynlonta is positioned as a single-agent therapy for third-line plus DLBCL, with rapid, deep, and durable efficacy, and manageable safety [4][20] 3. **Market Opportunity**: The potential peak revenue for Zynlonta in DLBCL is estimated to be between $500 million and $800 million, with a broader potential reaching $600 million to $1 billion as it expands into earlier lines of therapy and indolent lymphomas [20][21] 4. **Efficacy Data**: The best overall response rate (ORR) in the LOTIS-7 trial was reported at 89.8%, with a complete response (CR) rate of 77.6% among 49 efficacy-available patients [11][12] 5. **Patient Demographics**: The median age of patients in the study was 70 years, with a range from 26 to 85 years, and a median of one prior line of therapy [12][14] 6. **Safety Profile**: Neutropenia was the most common treatment-emergent adverse event, occurring in 32.7% of patients, consistent with known profiles of the individual drugs [11][14][39] 7. **Combination Therapy Rationale**: The combination of Zynlonta and glofitamab is expected to provide additive or synergistic efficacy due to their complementary mechanisms of action [8][10] 8. **Regulatory Strategy**: ADC Therapeutics plans to submit for regulatory approval and compendia listing following positive results from ongoing trials, with updates expected in 2026 [22][23] Additional Important Information 1. **Treatment Landscape**: The DLBCL treatment landscape is evolving, with a current 60/40 split between complex therapies (e.g., CAR-T, bispecifics) and broadly accessible therapies (e.g., ADCs, monoclonal antibodies) [5][6] 2. **Future Catalysts**: Multiple data catalysts are expected in 2026, including updates from LOTIS-5 and LOTIS-7 trials, which could significantly impact Zynlonta's market potential [21][22] 3. **Durability of Responses**: Among patients achieving CR, 33 out of 38 maintained their response as of the data cutoff, indicating promising durability [11][19] 4. **Comparative Efficacy**: The trial showed strong efficacy in both relapsed (100% ORR, 91.6% CR) and primary refractory (80% ORR, 64% CR) patient populations [18][30] 5. **Enrollment Trajectory**: The company is on track to complete enrollment of 100 patients in the LOTIS-7 trial by the first half of 2026, with a focus on maintaining a balanced patient population [43] This summary encapsulates the critical insights from the ADC Therapeutics conference call, highlighting the company's strategic direction, clinical trial outcomes, and market potential in the oncology sector.